Published in Clin Cancer Res on January 01, 2008
Assessing the human immune system through blood transcriptomics. BMC Biol (2010) 1.86
Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst (2012) 1.85
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst (2014) 1.58
RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer (2012) 1.43
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol (2010) 1.29
Predicting sample size required for classification performance. BMC Med Inform Decis Mak (2012) 1.27
Effects of sample size on robustness and prediction accuracy of a prognostic gene signature. BMC Bioinformatics (2009) 1.18
Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics (2010) 1.16
Microarray-based cancer prediction using single genes. BMC Bioinformatics (2011) 1.16
A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood (2008) 1.06
Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer (2008) 1.02
Factors influencing the statistical power of complex data analysis protocols for molecular signature development from microarray data. PLoS One (2009) 1.02
Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics (2015) 1.00
Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget (2015) 0.91
Investigating MicroRNA Expression Profiles in Pancreatic Cystic Neoplasms. Clin Transl Gastroenterol (2014) 0.89
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol (2014) 0.87
Lessons learned in the analysis of high-dimensional data in vaccinomics. Vaccine (2015) 0.86
Piwi-interacting RNAs and PIWI genes as novel prognostic markers for breast cancer. Oncotarget (2016) 0.86
Integrative computational biology for cancer research. Hum Genet (2011) 0.85
Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays. PLoS One (2011) 0.83
Investigation of radiosensitivity gene signatures in cancer cell lines. PLoS One (2014) 0.83
Genomic markers for decision making: what is preventing us from using markers? Nat Rev Clin Oncol (2009) 0.82
Interpretation of genomic data: questions and answers. Semin Hematol (2008) 0.82
Effects of sample size on differential gene expression, rank order and prediction accuracy of a gene signature. PLoS One (2013) 0.81
Determination of minimum training sample size for microarray-based cancer outcome prediction-an empirical assessment. PLoS One (2013) 0.79
Module-based prediction approach for robust inter-study predictions in microarray data. Bioinformatics (2010) 0.79
Profiling of Small Nucleolar RNAs by Next Generation Sequencing: Potential New Players for Breast Cancer Prognosis. PLoS One (2016) 0.78
Determination of sample size for a multi-class classifier based on single-nucleotide polymorphisms: a volume under the surface approach. BMC Bioinformatics (2014) 0.78
A prototype tobacco-associated oral squamous cell carcinoma classifier using RNA from brush cytology. J Oral Pathol Med (2013) 0.78
Discrimination of normal and esophageal cancer plasma proteomes by MALDI-TOF mass spectrometry. Dig Dis Sci (2015) 0.75
Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst (2007) 7.44
A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics (2003) 6.31
Analysis of gene expression data using BRB-ArrayTools. Cancer Inform (2007) 6.09
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics (2006) 1.77
Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A (2002) 1.72
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
Common cancer biomarkers. Cancer Res (2006) 1.56
Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics (2004) 1.45
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol (2007) 1.38
The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res (2002) 1.35
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Gene Set Expression Comparison kit for BRB-ArrayTools. Bioinformatics (2007) 1.28
Non-negative matrix factorization of gene expression profiles: a plug-in for BRB-ArrayTools. Bioinformatics (2009) 1.26
Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int (2014) 1.22
Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res (2008) 1.22
Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Med Genomics (2011) 1.17
Optimally splitting cases for training and testing high dimensional classifiers. BMC Med Genomics (2011) 1.13
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res (2011) 1.10
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov (2013) 1.10
Innate gene repression associated with Mycobacterium bovis infection in cattle: toward a gene signature of disease. BMC Genomics (2007) 1.07
Intra-subject variability in human bone marrow stromal cell (BMSC) replicative senescence: molecular changes associated with BMSC senescence. Stem Cell Res (2013) 1.05
Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res (2011) 1.04
Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidemiol Biomarkers Prev (2010) 1.03
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med (2013) 1.03
Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol (2003) 1.00
A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings. J Transl Med (2003) 0.99
The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics (2012) 0.95
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res (2005) 0.94
HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood (2005) 0.93
A comparison of phase II study strategies. Clin Cancer Res (2009) 0.93
Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog (2005) 0.92
Comment on 'Evaluation of the gene-specific dye bias in cDNA microarray experiments'. Bioinformatics (2005) 0.91
High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol (2005) 0.86
IRF5 gene polymorphisms in melanoma. J Transl Med (2012) 0.86
Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL. J Immunol (2002) 0.85
Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol (2006) 0.85
Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery. AIDS (2010) 0.85
Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling. Mol Ther (2012) 0.85
Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues. Cancer Epidemiol Biomarkers Prev (2012) 0.84
Antigen stimulation of peripheral blood mononuclear cells from Mycobacterium bovis infected cattle yields evidence for a novel gene expression program. BMC Genomics (2008) 0.84
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One (2012) 0.82
Partial immunity and vaccination for influenza. J Comput Biol (2010) 0.80
Findings on T cell specificity revealed by synthetic combinatorial libraries. J Immunol Methods (2002) 0.80
OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials. Brief Bioinform (2017) 0.79
Re: Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J Natl Cancer Inst (2011) 0.79
Combining positional scanning peptide libraries, HLA-DR transfectants and bioinformatics to dissect the epitope spectrum of HLA class II cross-restricted CD4+ T cell clones. J Immunol Methods (2009) 0.79
T-cell epitope prediction with combinatorial peptide libraries. J Comput Biol (2002) 0.79
Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. Hum Gene Ther Methods (2012) 0.77
Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus. J Transl Med (2015) 0.76
"Sequencing-grade" screening for BRCA1 variants by oligo-arrays. J Transl Med (2008) 0.75